The highly pathogenic avian influenza (HPAI) H5N1 virus remains to be one of the world's largest pandemic threats due to the emergence of new variants. The rapid evolution of new sub-lineages is currently the greatest challenge in vaccine development. In this study, we developed an epitope modified non-pathogenic H5N3 (A/duck/Singapore/97) vaccine for broad protection against influenza H5 subtype. H5N3 hemagglutinin (HA) mutant reassortant viruses with A/Puerto Rico/8/34 (PR8) backbone were generated by mutating amino acids at the 140th loop and 190th α-helix of hemagglutinin. The cross-neutralizing efficacy of reverse genetics-derived H5N3HA (RG-H5N3HA) mutants was confirmed by testing reactivity with reference chicken anti-H5N1 clade 2 virus sera. Furthermore, RG-H5N3HA mutant immunized mice induced cross-neutralizing antibodies and cross-protection against distinct H5N1 viral infection. Our findings suggest that the use of non-pathogenic H5 viruses antigenically related to HPAI-H5N1 allows for the development of broadly protective vaccines and reduces the need for biosafety level 3 (BSL3) containment facilities.
Introduction
Highly pathogenic avian influenza (HPAI) H5 subtype viruses cause serious outbreaks among chickens resulting in major economic losses in the poultry industry [1] . Vaccination remains to be the best method to prevent and control influenza. However, rapid emergence of antigenically drifted H5N1 viruses, timeline for vaccine strain selection, poor growth properties of selected vaccine strains and the need for high-level biocontainment facilities in vaccine manufacturing are major drawbacks of current influenza vaccine development [2] . Several research groups have tried to generate broadly protective immunogenicity via immunization with a combination of multiple hemagglutinins (HA) of H5N1 viruses [3, 4] . However, producing multivalent vaccines significantly increases vaccine cost and delays vaccine production. Thus, the use of a simple and broadly protective monovalent vaccine strain development method against H5 influenza will greatly reduce both the cost of vaccine development as well as the production time. Several research groups, in an effort to improve cross-protective efficacy of vaccine, have evaluated ancestral and consensus HA sequence-based vaccine designs [5, 6] . However, the input sequences do not accurately reflect the genetic diversity of H5N1 influenza virus.
Our present study thus focuses on generating broadly protective monovalent vaccine against H5N1 by modifying major neutralizing epitopes of HA, utilizing neutralizing monoclonal antibody (n-mAb) epitopes previously identified [7] . In this study, we used the HA of a non-pathogenic variant, influenza H5N3 (A/duck/Singapore/3/1997), which is antigenically similar to that of H5N1, as the Viruses 2018, 10, 2 2 of 8 backbone for the development of a broadly protective vaccine. Previous studies have shown that it induces cross protective immunogenicity against human H5N1 viruses from 1997 to 2004 [8] . However, the antigenic site of this non-pathogenic H5 vaccine strain does not match most H5N1 strains, especially that of clade 2 and its sub-lineages, which are known to predominantly circulate and cause human infections [9] .
In this present study, we modified the antigenic site by mutating amino acids in the 140th loop and the 190th α-helix of the HA of H5N3 (A/duck/Singapore/97) vaccine strain, which are located near the receptor binding site [7] and contribute to the strain-specific antigenic profile of the H5 viruses [10] . These modified HA were used to generate H5N3/PR8 reassortant virus which were then evaluated their neutralizing efficacy against H5N1 variants in a mouse model.
Materials and Methods

Ethics Statement
Experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Temasek Life Sciences Laboratory, National University of Singapore, Singapore (IACUC approval numbers TLL-16-025, TLL-17-019).
Viruses
The reassortant H5N1/PR8 viruses listed in Table 1 were previously generated by reverse genetics (RG) [11] . The listed H5N1 and H5N3 viruses (RG-H5N3, RG-H5N3 M0 , RG-H5N3 M1 and RG-H5N3 M2 ) were inactivated with binary ethylenimine as described previously [12] . 
Vaccine Construction
In this study, we used monoclonal antibodies (3H11, H and 3E8) recognizing neutralizing epitopes of H5HA for vaccine design. The neutralizing conformational epitopes of HA were previously mapped by the characterization of escape mutants with n-mAbs [7, 13] . The n-mAb 3H11 selected escape mutants at amino acid position 139 glycine or 140 serine (140th loop), n-mAb H selected escape mutants at amino acid positions 141 proline (140th loop) or 152 lysine, whereas n-mAb 3E8 selected escape mutants at amino acid position 189 arginine in the 190th α-helix (H5 numbering). We substituted amino acids at positions 138-141 and 189 in the HA of H5N3 (A/duck/Singapore/3/97) with amino acids found within the neutralizing epitopes of most clade 2 H5N1 viruses by site directed mutagenesis (Agilent Technologies, La Jolla, CA, USA). The resulting HA mutant with amino acid 189 (K to R) was designated H5N3HA M0 , mutant with amino acids NGRS replaced by QGSP at position 138-141 was M2 ) and neuraminidase (NA) (AY207510) from H5N3 and the six internal genes from A/Puerto Rico/8/1934 (PR8) viruses were generated [11] , and designated RG-H5N3, RG-H5N3HA M0 , RG-H5N3HA M1 and RG-H5N3HA M2 . The reactivity patterns of the vaccine constructs were subsequently confirmed with n-mAbs by immunofluorescence assay (IFA) [14] and the fluorescence signal was detected with an inverted fluorescence microscope (Olympus, London, UK). Next, we evaluated the replication efficacy of RG-H5N3 and its mutants in MDCK cells and embryonated chicken egg by HA titer [15] .
Confirmation of Antigenic Relatedness
Antigenic relatedness of vaccine constructs to clade 2 H5N1 viruses was then tested by viral neutralization study using reference chicken anti H5N1 sera (Table 1) . Chicken antisera against various H5N1 subtypes were produced in our previous study [11] . Briefly, groups of White Leghorn chickens (n = 5), were injected intramuscularly with inactivated H5N1 subtype ( Table 1) viruses emulsified in Montanide ISA-70 (SEPPIC, Paris, France) adjuvant. Chicken serum was collected 10 days after the second immunization. We then used these chicken sera to measure the vaccine constructs (H5N3-HA, H5N3-HA M0 , H5N3-HA M1 and H5N3-HA M2) antigenic relatedness to clade 2 H5N1 virus by microneutralization assay [16] .
Mice Immunization and Challenge
Specific-pathogen free female BALB/c mice (6 weeks old) were obtained from the Laboratory Animals Centre, National University of Singapore. Mice (10 per group) were vaccinated subcutaneously at days 0 and 28 with 100 µL (HA titer, 128) of inactivated RG-H5N3, RG-H5N3HA M1 , RG-H5N3HA M2 viruses with Freund's adjuvant (Sigma-Aldrich, St. Louis, MO, USA). Phosphate-buffered saline (PBS) was administered with the same adjuvant as a reference vaccine control. The mice serum collected 21 days after dose 2 (day 49) was evaluated by hemagglutination inhibition (HAI) titer [17] , anti-H5HA (A/Indonesia/5/2005) specific antibody titers by indirect ELISA [13] and VMN [16] against influenza viruses. In a separate study, mice (6 per group) were vaccinated with inactive RG-H5N3 or RG-H5N3HA M1 or RG-H5N3HA M2 vaccine with Freund's adjuvant on days 0 and 28. Four weeks after the final immunization, mice were anesthetized intraperitoneal (i.p.) with ketamine (100 mg/kg)/xylazine (20 mg/kg) and intranasally challenged with 50 µL (25 µL per naris) of 5 50% mouse lethal dose (MLD 50 ) of A/Hubei/1/2010 RG-H5N1 virus (clade 2.3.2.1). Mice were observed daily to monitor body weight, clinical signs of disease and mortality until day 14 after challenge. Mice were humanely euthanized with CO 2 inhalation if their body weight dropped to 75% of baseline weights.
Statistical Analysis
The HAI and VMN data are expressed as geometric mean ± standard errors (SE). An unpaired two-tailed Student's t-test was performed to determine the difference in the level of significance between the means of two groups (* p = 0.05; ** p = 0.01; *** p = 0.001).
Results and Discussion
To broaden the cross protective efficacy of the non-pathogenic H5N3 vaccine candidate, we modified amino acids of major neutralizing epitopes in the 140th loop and 190th α-helix region of HA which have previously been noted as very important determinants of protective immunity to clade-specific influenza H5N1 [7] . Beato et al. reported that the amino acid variations at the loop 140th loop and 190th α-helix may be responsible for antigenic differences of clade 2.2.1, 2.2.1.1 and 2.3.4 of clade 2 H5N1viruses [18] . Also, amino acid substitutions at the solvent-exposed positions 140, 141, and 189 of H5 HA correlate with changes in the antigenic signature of the virus [19] . The 190th α-helix, Viruses 2018, 10, 2 4 of 8 220th loop (amino acid residues 221-228) and the 130th loop (residues 134-138) are primarily involved in the formation of receptor binding site. In addition, amino acids in the 220th loop, at positions 226 and 228, have been linked closely to receptor binding specificity of avian or human [20] . Viruses with amino acids Q226 and G228 are specific for the avian (α-2,3 glycosidic linkage) sialic acid receptors, whereas viruses with amino acids L226 and S228 preferentially bind to human receptors (α-2,6 glycosidic linkage). The reactivity patterns of RG-H5N3 or RG-H5N3HA M1 or RG-H5N3HA M2 were confirmed with H5N1 n-mAbs (3H11, H, 3E8) by IFA (Figure 1) . The results showed that RG-H5N3HA M1 and RG-H5N3HA M2 reacted with mAbs 3H11 and H which recognize conformational epitopes (139 glycine, 141 proline), whereas only RG-H5N3HA M2 reacted with n-mAb 3E8 which recognizes conformational epitope (189 arginine) of HA0. These results indicate that the epitope modified H5N3-HA M1 and H5N3-HA M2 derived from H5N3HA have broader reactivity against previously unreactive H5N1 n-mAbs (3H11, 3E8, and H) produced against clade 2 specific viruses.
Viruses 2018, 10, 2 4 of 8 loop and 190th α-helix may be responsible for antigenic differences of clade 2.2.1, 2.2.1.1 and 2.3.4 of clade 2 H5N1viruses [18] . Also, amino acid substitutions at the solvent-exposed positions 140, 141, and 189 of H5 HA correlate with changes in the antigenic signature of the virus [19] . The 190th α-helix, 220th loop (amino acid residues 221-228) and the 130th loop (residues 134-138) are primarily involved in the formation of receptor binding site. In addition, amino acids in the 220th loop, at positions 226 and 228, have been linked closely to receptor binding specificity of avian or human [20] . Viruses with amino acids Q226 and G228 are specific for the avian (α-2,3 glycosidic linkage) sialic acid receptors, whereas viruses with amino acids L226 and S228 preferentially bind to human receptors (α-2,6 glycosidic linkage). The reactivity patterns of RG-H5N3 or RG-H5N3HAM1 or RG-H5N3HAM2 were confirmed with H5N1 n-mAbs (3H11, H, 3E8) by IFA (Figure 1) . The results showed that RG-H5N3HAM1 and RG-H5N3HAM2 reacted with mAbs 3H11 and H which recognize conformational epitopes (139 glycine, 141 proline), whereas only RG-H5N3HAM2 reacted with n-mAb 3E8 which recognizes conformational epitope (189 arginine) of HA0. These results indicate that the epitope modified H5N3-HAM1 and H5N3-HAM2 derived from H5N3HA have broader reactivity against previously unreactive H5N1 n-mAbs (3H11, 3E8, and H) produced against clade 2 specific viruses. We then used the reassortant viruses to measure mutant vaccine efficacy by virus microneutralization assay against reference chicken anti H5N1 sera. Table 1 shows that most of the clade 2 immunized chicken sera neutralization titers were significantly higher and also inhibited epitope modified RG-H5N3HAM2 vaccine strain to a larger extent as compared to other mutants (RG-H5N3HAM0, RG-H5N3HA M1) or RG-H5N3.
This indicates that RG-H5N3M2 viruses are more antigenically related to clade 2 H5N1 tested viruses and can thus induce a more significant immune response against clade 2 H5N1 influenza viruses. The reactivity of RG-H5N3M2 with reference chicken sera and neutralizing n-mAbs against H5N1 also shows the different antigenic properties from RG-H5N3. Additionally, we tested replication efficacy of RG-H5N3 or RG-H5N3 mutants in MDCK cells. The viral titers of RG-H5N3M1 and RG-H5N3M2 mutants showed 10 8.3 TCID50/mL and 10 8.0 TCID50/mL on 48 h post infection, respectively. Also, both RG-H5N3 mutant viruses were grown well in embryonated chicken eggs and showed 512 HA titer.
Furthermore, immunogenicity and cross-neutralizing efficacy of the epitope modified vaccine was evaluated in a mouse model. The results showed that mice immunized with RG-H5N3HAM2 We then used the reassortant viruses to measure mutant vaccine efficacy by virus microneutralization assay against reference chicken anti H5N1 sera. Table 1 shows that most of the clade 2 immunized chicken sera neutralization titers were significantly higher and also inhibited epitope modified RG-H5N3HA M2 vaccine strain to a larger extent as compared to other mutants (RG-H5N3HA M0 , RG-H5N3HA M1 ) or RG-H5N3.
This indicates that RG-H5N3 M2 viruses are more antigenically related to clade 2 H5N1 tested viruses and can thus induce a more significant immune response against clade 2 H5N1 influenza viruses. The reactivity of RG-H5N3 M2 with reference chicken sera and neutralizing n-mAbs against H5N1 also shows the different antigenic properties from RG-H5N3. Additionally, we tested replication efficacy of RG-H5N3 or RG-H5N3 mutants in MDCK cells. The viral titers of RG-H5N3 M1 and RG-H5N3 M2 mutants showed 10 8.3 TCID 50 /mL and 10 8.0 TCID 50 /mL on 48 h post infection, respectively. Also, both RG-H5N3 mutant viruses were grown well in embryonated chicken eggs and showed 512 HA titer.
Furthermore, immunogenicity and cross-neutralizing efficacy of the epitope modified vaccine was evaluated in a mouse model. The results showed that mice immunized with RG-H5N3HA M2 vaccine strain showed significantly (p > 0.001) enhanced HAI and cross-neutralizing antibody titers against most H5N1 clade 2 (2.1.3, 2.2.1, 2.3.2) viruses as compared to mice immunized with either (Figure 2A,B) . In addition, mice vaccinated with RG-H5N3 M2 construct significantly (** p < 0.01) induced HA of H5N1 specific immunoglobulin G (IgG) antibody titers when compared with RG-H5N3 vaccinated mice ( Figure 2C ). Higher antibody titer against H5N1HA could be the result of amino acid mutation in the H5N3HA epitope region at position 189R. The mutated H5N3HA epitope region is homologous to clade 2 H5N1HA, which enhances the strong IgG responses (2-fold higher) when compared to non-homologous epitope region in the RG-H5N3HA.
Viruses 2018, 10, 2 5 of 8 vaccine strain showed significantly (p > 0.001) enhanced HAI and cross-neutralizing antibody titers against most H5N1 clade 2 (2.1.3, 2.2.1, 2.3.2) viruses as compared to mice immunized with either RG-H5N3M1 or RG-H5N3 vaccine (Figure 2A,B) . In addition, mice vaccinated with RG-H5N3M2 construct significantly (** p < 0.01) induced HA of H5N1 specific immunoglobulin G (IgG) antibody titers when compared with RG-H5N3 vaccinated mice ( Figure 2C ). Higher antibody titer against H5N1HA could be the result of amino acid mutation in the H5N3HA epitope region at position 189R. The mutated H5N3HA epitope region is homologous to clade 2 H5N1HA, which enhances the strong IgG responses (2-fold higher) when compared to non-homologous epitope region in the RG-H5N3HA. The amino acid positions 140, 141 and 189 which are found on the surface-exposed membrane-distal receptor-binding region of the globular HA1 are likely to influence HAI titer as Viruses 2018, 10, 2 6 of 8 they are known to be predominant sites for antigenic variability among clade 2 viruses [19] . Hence, these higher cross-neutralizing antibody titers observed could be the result of the mutated amino acids at 138Q or 140S or 141P and 189R, present in all of the above tested viruses. Several previous studies reported that HAI and cross reactivity of antisera upon vaccination is substantially affected by amino acids located near the receptor binding sites [20, 21] and amino acids responsible for antigenic changes [22] . In this study, we constructed the RG-H5N3 M2 vaccine by mutating three amino acids at positions 140, 141 and 189. These three positions are found on the surface-exposed membrane-distal receptor binding region of the globular HA1, which are also predominant sites for antigenic variability among the clade 2 H5N1 viruses [19] and capable of enhancing antigenic relatedness to clade 2 H5N1 viruses (Table 1 ). These characteristics may enhance HAI and NT titer of RG-H5N3 M2 vaccine immunized serum against clade 2 H5N1 tested viruses. However, mice immunized with RG-H5N3 M1 showed significantly (p > 0.01; p > 0.05) higher HAI and neutralizing antibody titers against only clade 2.3.4 compared to mice immunized with RG-H5N3 M2 vaccine, likely due to the variant amino acid at position 189 (lysine). The amino acid arginine or lysine at position 189 on influenza H5 virus hemagglutinin, located in the receptor binding site is one of the major antigenic determinants. Stevens et al. [23] reported that the presence of an arginine at position 189 is characteristic of isolates from clades 2.1 and 2.2 but uncommon in those from clade 2.3.4, which predominantly have a lysine at this position.
Overall, the HAI and neutralizing titer results show that the amino acids at positions 138,140, 141 and 189 are key determinants for inducing cross-neutralizing antibodies against H5N1 viruses.
In addition, we tested the cross-protective efficacy of epitope modified vaccine approach in a mouse model. Four weeks after the final immunization, all vaccinated mice groups were challenged with 5 MLD 50 of A/Hubei/1/2010 H5N1 virus (clade 2.3.2.1). Mice immunized with RG-H5N3 M2 obtained 100% protection ( Figure 3A ) while RG-H5N3 M1 vaccinated mice showed only 30% protection. The infection was indicated by rapid loss in body weight of mice immunized with RG-H5N3 M1 or RG-H5N3 vaccine. However, mice immunized with RG-H5N3 M2 vaccine showed only mild decrease in body weight (up to 8%) on day 4 and regained their body weight rapidly ( Figure 3B ). The complete protection of RG-H5N3 M2 vaccine conclusively showed that the amino acid mutation at the 140th loop (140S and 141P) and 190th (189R) helix in the key epitope region of H5N3HA switches it to a clade 2 specific H5HA antigenic region and enhances the neutralizing antibodies, HAI titer and IgG response against clade 2 specific H5N1 viruses.
The amino acid positions 140, 141 and 189 which are found on the surface-exposed membranedistal receptor-binding region of the globular HA1 are likely to influence HAI titer as they are known to be predominant sites for antigenic variability among clade 2 viruses [19] . Hence, these higher crossneutralizing antibody titers observed could be the result of the mutated amino acids at 138Q or 140S or 141P and 189R, present in all of the above tested viruses. Several previous studies reported that HAI and cross reactivity of antisera upon vaccination is substantially affected by amino acids located near the receptor binding sites [20, 21] and amino acids responsible for antigenic changes [22] . In this study, we constructed the RG-H5N3M2 vaccine by mutating three amino acids at positions 140, 141 and 189. These three positions are found on the surface-exposed membrane-distal receptor binding region of the globular HA1, which are also predominant sites for antigenic variability among the clade 2 H5N1 viruses [19] and capable of enhancing antigenic relatedness to clade 2 H5N1 viruses (Table 1) . These characteristics may enhance HAI and NT titer of RG-H5N3M2 vaccine immunized serum against clade 2 H5N1 tested viruses. However, mice immunized with RG-H5N3M1 showed significantly (p > 0.01; p > 0.05) higher HAI and neutralizing antibody titers against only clade 2.3.4 compared to mice immunized with RG-H5N3M2 vaccine, likely due to the variant amino acid at position 189 (lysine). The amino acid arginine or lysine at position 189 on influenza H5 virus hemagglutinin, located in the receptor binding site is one of the major antigenic determinants. Stevens et al. [23] reported that the presence of an arginine at position 189 is characteristic of isolates from clades 2.1 and 2.2 but uncommon in those from clade 2.3.4, which predominantly have a lysine at this position.
In addition, we tested the cross-protective efficacy of epitope modified vaccine approach in a mouse model. Four weeks after the final immunization, all vaccinated mice groups were challenged with 5 MLD50 of A/Hubei/1/2010 H5N1 virus (clade 2.3.2.1). Mice immunized with RG-H5N3M2 obtained 100% protection ( Figure 3A ) while RG-H5N3M1 vaccinated mice showed only 30% protection. The infection was indicated by rapid loss in body weight of mice immunized with RG-H5N3M1 or RG-H5N3 vaccine. However, mice immunized with RG-H5N3M2 vaccine showed only mild decrease in body weight (up to 8%) on day 4 and regained their body weight rapidly ( Figure  3B ). The complete protection of RG-H5N3M2 vaccine conclusively showed that the amino acid mutation at the 140th loop (140S and 141P) and 190th (189R) helix in the key epitope region of H5N3HA switches it to a clade 2 specific H5HA antigenic region and enhances the neutralizing antibodies, HAI titer and IgG response against clade 2 specific H5N1 viruses.
Our findings show that non-pathogenic avian influenza viruses can be modified to produce broadly protecting vaccines against circulating HPAI H5 viruses by substituting amino acids based on the variation in the neutralizing epitopes of HA. Moreover, the use of a non-pathogenic-based vaccine as a backbone allows for higher growth titers to be obtained and also eliminates the need to use BSL3 containment facilities for vaccine production. Our findings show that non-pathogenic avian influenza viruses can be modified to produce broadly protecting vaccines against circulating HPAI H5 viruses by substituting amino acids based on the variation in the neutralizing epitopes of HA. Moreover, the use of a non-pathogenic-based vaccine as a backbone allows for higher growth titers to be obtained and also eliminates the need to use BSL3 containment facilities for vaccine production.
